Sarepta Therapeutics Court & Legal Update
Sarepta Therapeutics entered into a settlement agreement with REGENXBIO, the University of Pennsylvania, and Catalent to resolve pending patent infringement litigation regarding the '274 and '617 patents. Sarepta will pay a lump sum of $39.0 million to REGENXBIO in exchange for a release of claims and a covenant not to sue regarding Sarepta's gene therapy products using the AAVrh74-based capsid, including ELEVIDYS. The settlement resolves all pending litigations with prejudice and includes no admission of liability.
- Counterparty
- REGENXBIO Inc.